On July 31st, the U.S. Food and Drug Administration’s Center for Veterinary Medicine (FDA-CVM) announced label extensions for 35% PEROX-AID for use in freshwater finfish!
Previously, 35% PEROX-AID was approved for the control of mortality in: (1) freshwater-reared finfish eggs due to Saprolegniasis; (2) freshwater-reared salmonids due to Bacterial Gill Disease (Flavobacterium branchiophilum); and (3) freshwater-reared coolwater finfish and channel catfish due to external columnaris disease (Flavobacterium columnare).
35% PEROX-AID is now also approved for: (1) controlling mortality in all coldwater finfish (including all salmonids), and all fingerling and adult freshwater-reared coolwater and warmwater finfish due to Saprolegniasis. This will allow for the treatment of Saprolegniasis in life stages other than eggs; (2) controlling Gyrodactylus spp. in freshwater-reared salmonids; and (3) controlling mortality in all freshwater-reared warmwater finfish, including hybrid catfish and blue catfish, due to external columnaris (Flavobacterium columnare).
According to the FDA press release, “This approval will help provide a critical treatment for improving fish health. The agency also anticipates that resource management agencies will use this approved treatment for aiding in the restoration of certain freshwater fish populations.”
Recent Comments